Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| R01AI184756 | U.S. NIH Grant/Contract | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National Institute of Allergy and Infectious Diseases (NIAID) | NIH |
| Kenya Medical Research Institute | OTHER |
| Walter Reed Army Institute of Research (WRAIR) | FED |
Not provided
Not provided
Not provided
Not provided
The CLEAN (ChLorine to reduce Enteric and Antibiotic resistant infections in Neonates) cluster randomized controlled trial in western Kenya will evaluate the impact of a multi-component chlorination intervention in health care facilities on maternal and neonatal health. Intervention facilities will receive a passive chlorination technology for water supply treatment and a reliable supply of sodium hypochlorite disinfectant. Both intervention and treatment facilities will receive infection prevention and control messaging. The goal of the study is to evaluate the impact of the intervention on bacterial contamination of water supply, on staff hands, and on high-touch surfaces in maternity wards, and the following outcomes among facility-born neonates and their mothers: (1) gut carriage of bacterial pathogens associated with sepsis one week post-birth, (2) gut carriage of antibiotic resistant bacteria one week post-birth, and (3) symptoms of possible serious bacterial infection one week following birth.
The proportion of births occurring at healthcare facilities is rising globally, yet healthcare facilities in low-income settings have been found to be highly contaminated with bacterial pathogens, including antibiotic resistant pathogens. There is a need for effective strategies to reduce contamination in healthcare facilities in order to reduce infection risks among facility-born neonates. In this trial, medium-sized public health facilities will be randomized to control or to receive an intervention consisting of passive chlorination for water supply treatment and a reliable supply of chlorine disinfectant. Reliable supply is randomized as either (a) an electrochlorinator for on-site production or (b) bulk chlorine delivery.
This cluster randomized controlled trial will enroll 36 health facilities to generate rigorous evidence on the maternal and neonatal health benefits of chlorinated water supply paired with reliable supplies of chlorine disinfectant. This study has the following aims: 1) determine the impact of the intervention on pathogenic and antibiotic resistant bacterial contamination in water supplies, on high-touch surfaces, and on healthcare worker hands, 2) quantify intervention effects on gut colonization of mothers and neonates by a panel of pathogenic and antibiotic resistant bacteria species linked to serious infection, using molecular and culture-based methods, and 3) follow up with mother-neonate dyads to measure intervention effects on symptoms of possible serious bacterial infection in the week following birth. Data collection will be for a duration of 24 months.
Infection prevention through effective water, sanitation, and hygiene (WASH) has been cited by national action plans as a key tool in the fight against antimicrobial resistance and, while global data show dire WASH conditions in low- and middle-income (LMIC) health facilities, there exists very little guidance for implementing effective interventions. The overarching goal is to generate actionable evidence to inform investments in chlorination at health facilities to improve maternal and neonatal health and reduce the threat of antibiotic resistant infections.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Control | Active Comparator | Control group. At the conclusion of the trial, facilities will receive a chlorine doser. |
|
| Multi-component chlorine intervention | Experimental | Health care facilities will receive one or more inline chlorine dosers that will automatically chlorinate all water accessed by the maternity wards. Intervention facilities will also be randomized to either receive an electrochlorinator for on-site production of liquid chlorine solution or to receive bulk chlorine deliveries. Chlorine will be use to refill the chlorine dosers and for surface disinfection. Facilities will also receive hardware to facilitate surface disinfection. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| chlorination for water disinfection and surface disinfection | Device |
|
| Measure | Description | Time Frame |
|---|---|---|
| Possible serious bacterial infection in neonate | Incidence of one or more of the following severe infection symptoms of neonates based on WHO criteria for possible serious bacterial infection:
| From birth to 7 days post birth |
| Possible maternal sepsis | Any of the following listed with fever or hypothermia:
| From birth to 7 days post birth |
| Neonatal infection with at least one bacterial pathogen | Detection of any pre-specified bacterial pathogen detected by qPCR in infant rectal swabs (among swab subset of participants) Includes: ETEC, STEC, EPEC, EAEC, EIEC, EHEC O157:H7, Escherichia coli/Shigella, Shigella spp, Shigella flexneri, Salmonella spp., Salmonella enteritidis, Salmonella typhi, Campylobacter jejuni/coli, Staphylococcus aureus, Klebsiella pneumoniae, Streptococcus pneumoniae, Streptococcus agalactiae (Group B strep), Serratia marcescens, Pseudomonas aeruginosa, Acinetobacter baumannii, Clostridium difficile, Vibrio cholerae | 7 days after birth |
| Measure | Description | Time Frame |
|---|---|---|
| Any symptom or sign of infection in neonate | One or more of the following symptoms: Difficulty feeding, Hyperthermia/fever, Hypothermia, Tachypnea, Severe chest indrawing, Convulsions, Movement only when stimulated/no movement, Bulging fontanel, Labored breathing, Skin infection, Umbilical redness, Oozing ears, Diarrhea, Three or more loose or watery stools in a 24 hour period, Vomiting, Cyanosis, Cough, Runny nose or congestion, Tachycardia (>160 bpm at rest) |
| Measure | Description | Time Frame |
|---|---|---|
| Rectal colonization with individual bacterial pathogens (neonates) | Detection of individual bacterial pathogen by qPCR or by culture (see list in secondary outcomes) | 7 days post birth |
| Rectal colonization with individual bacterial pathogens (mothers) |
Facility Inclusion Criteria:
Participant Inclusion Criteria:
Facility Exclusion Criteria:
Participant Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Amy J Pickering, PhD | Contact | 1-510-410-2666 | amyjanel@gmail.com | |
| Yoshika Crider, PhD | Contact | 1-785-550-5227 | ycrider@berkeley.edu |
| Name | Affiliation | Role |
|---|---|---|
| Amy J Pickering, PhD | University of California, Berkeley | Principal Investigator |
| Phelgona Otieno, PhD | Kenya Medical Research Institute | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of California, Berkeley | Active, not recruiting | Berkeley | California | 94720 | United States | |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 35700262 | Background | Lindmark M, Cherukumilli K, Crider YS, Marcenac P, Lozier M, Voth-Gaeddert L, Lantagne DS, Mihelcic JR, Zhang QM, Just C, Pickering AJ. Passive In-Line Chlorination for Drinking Water Disinfection: A Critical Review. Environ Sci Technol. 2022 Jul 5;56(13):9164-9181. doi: 10.1021/acs.est.1c08580. Epub 2022 Jun 14. | |
| 31402005 | Background | Pickering AJ, Crider Y, Sultana S, Swarthout J, Goddard FG, Anjerul Islam S, Sen S, Ayyagari R, Luby SP. Effect of in-line drinking water chlorination at the point of collection on child diarrhoea in urban Bangladesh: a double-blind, cluster-randomised controlled trial. Lancet Glob Health. 2019 Sep;7(9):e1247-e1256. doi: 10.1016/S2214-109X(19)30315-8. |
Not provided
Not provided
Any data shared will be de-identified. Participants will not be contacted or re-consented for future sharing or accessing data through repositories. Privacy and confidentiality protections will be consistent with applicable local laws in Kenya. Data will be de-identified prior to sharing. All data sharing plans will be reviewed and approved by the respective institutional review boards at all participating institutions and will be reviewed during the informed consent process with caregivers.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Lab technicians will be masked to intervention status of samples received. A subset of investigators will be masked to outcomes by intervention status until data collection is complete.
|
| infection prevention and control messaging | Behavioral | Infection prevention and control guidance and messaging |
|
| From birth until 7 days post birth |
| Any symptom or sign of infection in mother | One or more of the following symptoms: Hypothermia, Fever, Foul smelling vaginal discharge, Fits/convulsions, Tachycardia (>100 bpm at rest), Low blood pressure, Diarrhea (self-defined), Difficulty breathing, Jaundice, Decreased urination or difficult or painful urination, Confusion or altered mental state, Mastitis, Chills, Body aches, Low appetite, Lower abdominal pain, Three or more loose or watery stools in a 24 hour period, Vomiting, Cough, Runny nose or congestion, Chest pain, Bloody stool, Skin infection | From birth to 7 days post birth |
| Clinical diagnosis of sepsis in neonate | Abstracted diagnosis from medical charts OR self-reported diagnosis confirmed by clinician | From birth to 7 days post birth |
| Clinical diagnosis of sepsis in mother | Abstracted diagnosis from medical charts OR self-reported diagnosis confirmed by clinician | From birth to 7 days post birth |
| Neonatal mortality | Report of neonatal death up to 28 days | From birth to 28 days after birth |
| Maternal mortality | Report of maternal death | From birth to 28 days after birth |
| Neonatal rectal colonization with at least one bacterial pathogen by culture | Detection of any pre-specified bacterial pathogen detected by culture in neonate rectal swabs (among swab subset of participants) Includes: Acinetobacter spp., Pseudomonas spp., Salmonella spp., Shigella, Staphylococcus aureus, Group B streptococcus | 7 days after birth |
| Maternal rectal colonization with at least one bacterial pathogen by culture-based method | Detection of any pre-specified bacterial pathogen detected by culture in maternal rectal swabs (among swab subset of participants) Acinetobacter spp., Pseudomonas spp., Salmonella spp., Shigella spp., Staphylococcus aureus, Group B streptococcus | 7 days postpartum |
| Number of clinically relevant antibiotic resistance genes (ARGs) detected in neonatal rectal swabs | Measured by qPCR. Includes: resistance to quinolone, macrolide, sulfonamide, tetracycline, vancomycin, aminoglycoside, beta-lactams (cephalosporin, penicillin, ampicillin) , carbapenem, colistin | 7 days post birth |
| Rectal colonization with one or more antibiotic resistant bacteria (neonates) | Detection of ESBL enterobacteriaceae by culture in rectal swabs Includes: Klebsiella spp./Enterobacter/Citrobacter spp. (KEC), Acinetobacter spp., Pseudomonas spp., E. coli | 7 days post birth |
| Rectal colonization with one or more antibiotic resistant bacteria (mothers) | Detection of ESBL enterobacteriaceae by culture in rectal swabs Includes: Klebsiella spp./Enterobacter/Citrobacter spp. (KEC), Acinetobacter spp., Pseudomonas spp., E. coli | 7 days postpartum |
| Number of bacterial pathogens in rectal swabs (neonates) | Number of unique bacterial pathogens (see pre-specified list above) detected by qPCR | 7 days post birth |
| Number of bacterial pathogens in rectal swabs (mothers) | Number of unique bacterial pathogens (see pre-specified list above) by culture | 7 days postpartum |
Detection of individual bacterial pathogen (see pre-specified list in secondary outcomes) by culture or qPCR
| 7 days postpartum |
| Presence of individual ARGs in neonatal rectal swabs | Presence/absence of pre-specified clinically relevant ARGs by qPCR | 7 days post birth |
| Presence and concentration of bacterial pathogens on high touch surfaces | Measured by culture-based assays Includes: Acinetobacter spp., Pseudomonas spp., Salmonella spp., Shigella, Staphylococcus aureus, Group B streptococci | Measured quarterly over 24 months post intervention delivery (every 3 months) |
| Presence and concentration of antibiotic resistant bacterial pathogens on high touch surfaces | Detection of ESBL enterobacteriaceae by culture in surface swabs Includes: Klebsiella spp./Enterobacter/Citrobacter spp. (KEC), Acinetobacter spp., Pseudomonas spp., E. coli | Measured quarterly over 24 months post intervention delivery (every 3 months) |
| Proportion of water samples meeting WHO "safe" criteria | Measured as <1 CFU E. coli per 100ml water tested by culture | Measured quarterly over 24 months post intervention delivery (every 3 months) |
| Concentration of E. coli / 100 ml water | Measured by culture-based membrane filtration assay | Measured quarterly over 24 months post intervention delivery (every 3 months) |
| Presence and concentration of E. coli and total coliform on healthcare staff hands | Measured by membrane filtration culture assay | Measured quarterly over 24 months post intervention delivery (every 3 months) |
| Presence and concentration of antibiotic resistant bacterial pathogens on healthcare staff hands | Detection of ESBL enterobacteriaceae by culture in hand rinses and swabs Includes: Klebsiella spp./Enterobacter/Citrobacter spp. (KEC), Acinetobacter spp., Pseudomonas spp., E. coli | Measured quarterly over 24 months post intervention delivery (every 3 months) |
| Proportion of water supply samples with detectable free chlorine residual in water | Measured as >0.1 ppm by DPD method | Measured quarterly over 24 months post intervention delivery (every 3 months) |
| Lillian Musila, PhD |
| Walter Reed Army Institute of Research-Africa |
| Principal Investigator |
| Kenya Medical Research Institute |
| Recruiting |
| Nairobi |
| Kenya |
|
| ID | Term |
|---|---|
| D018805 | Sepsis |
| ID | Term |
|---|---|
| D007239 | Infections |
| D018746 | Systemic Inflammatory Response Syndrome |
| D007249 | Inflammation |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided